Mabqi today announced that Syndivia had exercised an option with Mabqi on a jointly discovered antibody-drug conjugate (ADC) acquired by a Pharma company.
This option was exercised as part of a research collaboration launched in 2023 between Mabqi and Syndivia to discover and develop a new ADC drug candidate with indications in Prostate Cancer.
This step marked a major milestone in the collaboration between the two companies, combining their complementary strengths: Mabqi’s LiteMab Antibody Discovery Studio and Syndivia’s GeminiMab ADC platform. The antibody was discovered through the LiteMab discovery studio, tailored to meet the precise functional requirements of the final drug candidate, including affinity, developability, and pharmacological properties. Syndivia subsequently designed the final ADC candidate and carried out the full preclinical characterization.
“We are delighted that Syndivia has exercised this option and successfully demonstrated the potency of this candidate within such a short timeframe”, said Sylvain Yon, CEO of Mabqi. “The combination of our LiteMab Antibody Discovery Studio with Syndivia’s cutting-edge conjugation platform has proven to be a highly effective approach, enabling the rapid discovery of a drug candidate with strong clinical potential. Through this collaboration, Mabqi reinforces its focus on advancing research in areas of significant medical need by joining forces with partners who contribute complementary expertise and technologies, creating synergies that accelerate the discovery of new treatments for patients.”
For more details, read the full press release.
More information on the antibody licenced to Syndivia available here.
